Effect of a mesitylene-based ligand cap on the relaxometric properties of Gd(III) hydroxypyridonate MRI contrast agents

Contrast Media and Molecular Imaging

Volumn 4, Issue 5, 2009, Pages 220-229

  Werner, Eric J ^a   Botta, Mauro ^b   Aime, Silvio ^c   Raymond, Kenneth N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Aggregation; Gadolinium; Hydroxypyridinone (HOPO); Mesityl; MRI contrast agent; Relaxivity

Indexed keywords

1,3,5 TRIMETHYLBENZENE; CATECHOL; CONTRAST MEDIUM; GADOLINIUM MESITYLENE BIS(1 MESITYLENE 3,2 HYDROXYPYRIDINONE)TEREPHTHALAMIDE; GADOLINIUM MESITYLENE BIS(1 MESITYLENE 3,2 HYDROXYPYRIDINONE)TEREPHTHALAMIDE POLYETHYLENE GLYCOL 450; GADOLINIUM TRIS(2 AMINOETHYL)AMINE BIS(1 MESITYLENE 3,2 HYDROXYPYRIDINONE)TEREPHTHALAMIDE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG STRUCTURE; DRUG SYNTHESIS; LIGAND BINDING; NUCLEAR MAGNETIC RESONANCE; PH; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

BENZENE DERIVATIVES; CONTRAST MEDIA; HYDROGEN-ION CONCENTRATION; LIGANDS; MAGNETIC RESONANCE IMAGING; ORGANOMETALLIC COMPOUNDS; SOLUTIONS; TEMPERATURE;

EID: 71649096231     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.281     Document Type: Article

References (35)

1. Werner EJ, Kozhukh J, Botta M, Moore EG, Avedano S, Aime S, Raymond KN. 2009; 1,2-Hydroxypyridonate/terephthalamide complexes of gadolinium(III): synthesis, stability, relaxivity, and water exchange properties. Inorg. Chem. 48: 277-286.
2. Aime S, Botta M, Terreno E. 2005; Gd(III)-based contrast agents for MRI. In Advances in Inorganic Chemistry, Vol.57 van Eldik R, Bertini I (eds). Elsevier: San Diego, 173-237.
3. Caravan P. 2006; Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem. Soc. Rev. 35: 512-523.
4. Merbach AE, Tóth É (eds). 2001; The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging. Wiley: Chichester, 2001.
5. Caravan P, Ellison J, McMurry T, Lauffer R. 1999; Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications. Chem. Rev. 99: 2293-2352.
6. Raymond KN, Pierre VC. 2005; Next generation, high relaxivity gadolinium MRI agents. Bioconjug. Chem. 16: 3-8.
7. Werner EJ, Datta A, Jocher CJ, Raymond KN. 2008; High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging. Angew. Chem. Int. Ed. 47: 8568-8580.
8. Hajela SP, Johnson AR, Xu J, Sunderland CJ, Cohen SM, Caulder DL, Raymond KN. 2001; Synthesis of homochiral tris(2-alkyl- 2-aminoethyl)amine derivatives from chiral a-amino aldehydes and their application in the synthesis of water soluble chelators. Inorg. Chem. 40: 3208-3216.
9. O'Sullivan B, Doble DMJ, Thompson MK, Siering C, Xu J, Botta M, Aime S, Raymond KN. 2003; The effect of ligand scaffold size on the stability of tripodal hydroxypyridonate gadolinium complexes. Inorg. Chem. 42: 2577-2583.
10. Werner EJ, Avedano S, Botta M, Hay BP, Moore EG, Aime S, Raymond KN. 2007; Highly soluble tris-hydroxypyridonate Gd(III) complexes with increased hydration number, fast water exchange, slow electronic relaxation, and high relaxivity. J. Am. Chem. Soc. 129: 1870-1871.
11. Harris WR, Raymond KN. 1979; Ferric ion sequestering agents. 3. The spectrophotometric and potentiometric evaluation of two new enterobactin analogs: 1,5,9-N,N″,N″-tris(2,3-dihydroxybenzoyl) cyclotriazatridecane and 1,3,5-N,N′,N″-tris(2,3-dihydroxybenzoyl) triaminomethylbenzene. J. Am. Chem. Soc. 101: 6534-6541.
12. Harris WR, Weitl FL, Raymond KN. 1979; Synthesis and evaluation of an enterobactin model compound. 1,3,5-Tris-(2,3-dihydroxybenzoylaminomethyl) benzene and its iron(III) complex. J. Chem. Soc., Chem. Commun. 177-178.
13. Hay BP, Dixon DA, Vargas R, Garza J, Raymond KN. 2001; Structural criteria for the rational design of selective ligands. 3. Quantitative structure-stability relationship for iron(III) complexation by triscatecholamide siderophores. Inorg. Chem. 40: 3922-3935.
14. Loomis LD, Raymond KN. 1991; Solution equilibria of enterobactin and metal-enterobactin complexes. Inorg. Chem. 30: 906-911.
15. Hou Z, Stack TDP, Sunderland CJ, Raymond KN. 1997; Enhanced iron(III) chelation through ligand predisposition: syntheses, structures and stability of tris-catecholate enterobactin analogs. Inorg. Chim. Acta 263: 341-355.
16. Piyamongkol S, Zhou T, Liu ZD, Khodr HH, Hider RC. 2005; Design and characterization of novel hexadentate 3-hydroxypyridin-4-one ligands. Tetrahedron Lett. 46: 1333-1336. (Pubitemid 40186752)
17. Pierre VC, Botta M, Aime S, Raymond KN. 2006; Substituent effects on Gd(III)-based MRI contrast agents: optimizing the stability and selectivity of the complex and the number of coordinated water molecules. Inorg. Chem. 45: 8355-8364.
18. Gorden AEV, Xu J, Raymond KN, Durbin P. 2003; Rational design of sequestering agents for plutonium and other actinides. Chem. Rev. 103: 4207-4282.
19. Doble DMJ, Melchior M, O'Sullivan B, Siering C, Xu J, Pierre VC, Raymond KN. 2003; Toward optimized high-relaxivity MRI agents: the effect of ligand basicity on the thermodynamic stability of hexadentate hydroxypyridonate/ catecholate gadolinium(III) complexes. Inorg. Chem. 42: 4930-4937.
20. III complexes. J. Am. Chem. Soc. 123: 10758-10759.
21. Thompson MK, Doble DMJ, Tso LS, Barra S, Botta M, Aime S, Raymond KN. 2004; Hetero-tripodal hydroxypyridonate gadolinium complexes: syntheses, relaxometric properties, water exchange dynamics, and human serum albumin binding. Inorg. Chem. 43: 8577-8586.
22. Pierre VC, Botta M, Aime S, Raymond KN. 2006; Tuning the coordination number of hydroxypyridonate-based gadolinium complexes: implications for MRI contrast agents. J. Am. Chem. Soc. 128: 5344-5345.
23. Pierre VC. 2005; Macromolecular gadolinium complexes for use as contrast agents in medical magnetic resonance imaging. Ph. D. Thesis. University of California, Berkeley.
24. Accardo A, Tesauro D, Roscigno P, Gianolio E, Paduano L, D'Errico G, Pedone C, Morelli G. 2004; Physicochemical properties of mixed micellar aggregates containing CCK peptides and Gd complexes designed as tumor specific contrast agents in MRI. J. Am. Chem. Soc. 126: 3097-3107.
25. Fatin-Rouge N, Tóth É, Meuli R, Bünzli J-CG. 2004; Enhanced imaging properties of a GdIII complex with unusually large relaxivity. J. Alloys Compd 374: 298-302.
26. Tóth É, Bolskar RD, Borel A, Gonzalez G, Helm L, Merbach AE, Sitharaman B, Wilson LJ. 2005; Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents. J. Am. Chem. Soc. 127: 799-805.
27. x: nanoscale aggregation studies of two metallofullerene MRI contrast agents in aqueous solution. Nano Lett. 4: 2373-2378.
28. Stubbs M, McSheehy PMJ, Griffiths JR, Bashford CL. 2000; Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today 6: 15-19.
29. Tannock IF, Rotin D. 1989; Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49: 4373-4384. (Pubitemid 19208329)
30. 10. J. Am. Chem. Soc. 127: 9368-9369.
31. Fatin-Rouge N, Tóth É, Perret D, Backer RH, Merbach AE, Bünzli J-CG. 2000; Lanthanide podates with programmed intermolecular interactions: luminescence enhancement through association with cyclodextrins and unusually large relaxivity of the gadolinium self-aggregates. J. Am. Chem. Soc. 122: 10810-10820.
32. Xu J, Churchill DG, Botta M, Raymond KN. 2004; Gadolinium(III) 1,2-hydroxypyridonate-based complexes: toward MRI contrast agents of high relaxivity. Inorg. Chem. 43: 5492-5494.
33. Xu J, Franklin SJ, Whisenhunt DW, Raymond KN. 1995; Gadolinium complex of tris[(3-hydroxy-1-methyl- 2-oxo-1,2-didehydropyridine- 4-carboxamido)ethyl]- amine: a new class of gadolinium magnetic resonance relaxation agents. J. Am. Chem. Soc. 117: 7245-7246.
34. Venuti MC, Rastetter WH, Neilands JB. 1979; 1,3,5-tris(N,N′, N″-2,3- dihydroxybenzoyl)aminomethylbenzene, a synthetic iron chelator related to enterobactin. J. Med. Chem. 22: 123-124.
35. Weitl FL, Raymond KN. 1979; Ferric ion sequestering agents. 1. Hexadentate O-bonding N,N′,N″-tris(2,3-dihydroxybenzoyl) derivatives of 1,5,9-triazacyclotridecane and 1,3,5-triaminomethylbenzene. J. Am. Chem. Soc. 101: 2728-2731.